Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company known for innovative medicines in HIV/AIDS, viral hepatitis, COVID-19, oncology, and inflammation. With a market cap of around $155 billion, it is a major player in healthcare and biotech.

Analysts predict GILD will report a Q4 profit of $1.86 per share, slightly down from the year-ago quarter. Expectations for fiscal 2025 show an EPS of $8.14, up 76.2% from fiscal 2024, with a forecasted 4.8% rise to $8.53 in fiscal 2026.

GILD has seen a 36.3% surge in the past year, outperforming the S&P 500 and the Health Care Select Sector SPDR ETF. Investors are optimistic about new product approvals and pipeline progress, especially with the FDA approval and commercial rollout of Yeztugo, a new HIV prevention product.

Analysts rate GILD as a “Strong Buy,” with a consensus price target of $135.67, suggesting an 8.6% potential upside from current levels. This article is for informational purposes only and was originally published on Barchart.com.

Read more at Yahoo Finance: Gilead Sciences Earnings Preview: What to Expect